Genome-wide studies in multiple myeloma identify XPO1/CRM1 as a critical target validated using the selective nuclear export inhibitor KPT-276-Reference-Cited by-同舟云学术

Genome-wide studies in multiple myeloma identify XPO1/CRM1 as a critical target validated using the selective nuclear export inhibitor KPT-276

Published:2013-06-11 Issue:12 Volume:27 Page:2357-2365
ISSN:0887-6924
Container-title:Leukemia
language:en
Short-container-title:Leukemia

Author:

Schmidt J,Braggio E,Kortuem K M,Egan J B,Zhu Y X,Xin C S,Tiedemann R E,Palmer S E,Garbitt V M,McCauley D,Kauffman M,Shacham S,Chesi M,Bergsagel P L,Stewart A K

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Cancer Research,Hematology

Link

http://www.nature.com/articles/leu2013172.pdf

Reference33 articles.

1. Kumar SK, Rajkumar SV, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood 2008; 111: 2516–2520.

2. Brenner H, Gondos A, Pulte D . Recent major improvement in long-term survival of younger patients with multiple myeloma. Blood 2008; 111: 2521–2526.

3. Tiedemann RE, Zhu YX, Schmidt J, Shi CX, Sereduk C, Yin H et al. Identification of molecular vulnerabilities in human multiple myeloma cells by RNA interference lethality screening of the druggable genome. Cancer Res 2012; 72: 757–768.

4. Pellom ST Jr, Shanker A . Development of proteasome inhibitors as therapeutic drugs. J Clin Cell Immunol 2012; S5: 5.

5. Xu D, Grishin NV, Chook YM . NESdb: a database of NES-containing CRM1 cargoes. Mol Biol Cell 2012; 23: 3673–3676.

Cited by 144 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Selinexor combined bortezomib, lenalidomide, and dexamethasone for newly diagnosed multiple myeloma with extramedullary disease: a multicenter study;2024-08-27

2. Michael Acceptors as Anti-Cancer Compounds: Coincidence or Causality?;International Journal of Molecular Sciences;2024-06-01

3. A novel application of XPO1 inhibition for the treatment of myelofibrosis;Blood Neoplasia;2024-06

4. Beyond oncology: Selinexor’s journey into anti-inflammatory treatment and long-term management;Frontiers in Immunology;2024-05-10

5. Therapeutic progress in relapsed/refractory multiple myeloma;Annals of Hematology;2024-04-13